Pharmaceutical company Daiichi Sankyo (a Japanese concern with a market capitalization of $34.6 billion) has partnered with technology company Tempus AI to accelerate the clinical development of an antibody drug conjugate (ADC) program in oncology.[1][2] ADC is a treatment approach that delivers drugs directly to tumor cells and targets specific antigens on the surface of the cancer, minimizing damage to healthy tissues.[3] As part of the collaboration, Daiichi Sankyo will use Tempus' proprietary models and AI tools, including PRISM2 – an advanced multimodal model that combines pathological images and clinical data to generate diagnostic and predictive insights.[1][2] Both companies will combine clinical and preclinical research data from Daiichi Sankyo with large-scale real-world data from Tempus to discover new biomarkers and stratify patients.[1][2] The goal is to develop AI models to optimize patient selection and increase the likelihood of success of a new ADC, and these models will be deployed in the Tempus oncology database to create detailed response maps and benchmark control groups for future clinical trials.[1][2] Daiichi Sankyo achieved 14 percent revenue growth in the last twelve months.[2] The financial terms of cooperation and specific timetables for the development of the program have not been published.[2]